IN2014CN04935A - - Google Patents

Info

Publication number
IN2014CN04935A
IN2014CN04935A IN4935CHN2014A IN2014CN04935A IN 2014CN04935 A IN2014CN04935 A IN 2014CN04935A IN 4935CHN2014 A IN4935CHN2014 A IN 4935CHN2014A IN 2014CN04935 A IN2014CN04935 A IN 2014CN04935A
Authority
IN
India
Prior art keywords
tumor
tissues
probability
invention describes
gene
Prior art date
Application number
Other languages
English (en)
Inventor
Moni Abraham Kuriakose
Amritha Suresh
Original Assignee
Moni Abraham Kuriakose
Amritha Suresh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moni Abraham Kuriakose, Amritha Suresh filed Critical Moni Abraham Kuriakose
Publication of IN2014CN04935A publication Critical patent/IN2014CN04935A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IN4935CHN2014 2011-12-31 2012-12-31 IN2014CN04935A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161631291P 2011-12-31 2011-12-31
PCT/IB2012/057844 WO2013098797A2 (en) 2011-12-31 2012-12-31 Diagnostic tests for predicting prognosis, recurrence, resistance or sensitivity to therapy and metastatic status in cancer

Publications (1)

Publication Number Publication Date
IN2014CN04935A true IN2014CN04935A (enExample) 2015-09-18

Family

ID=48698732

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4935CHN2014 IN2014CN04935A (enExample) 2011-12-31 2012-12-31

Country Status (3)

Country Link
US (1) US20140342946A1 (enExample)
IN (1) IN2014CN04935A (enExample)
WO (1) WO2013098797A2 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0913578A2 (pt) 2008-05-14 2017-06-06 Dermtech Int diagnose de melanoma e lentigo solar por análise de ácido nucléico
ES2859645T3 (es) 2013-03-14 2021-10-04 Mayo Found Medical Education & Res Detección de neoplasia
CN103525916B (zh) * 2013-09-24 2016-06-15 浙江大学医学院附属第四医院 评估肝细胞癌预后的试剂盒及rffl的应用
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
WO2016160454A1 (en) 2015-03-27 2016-10-06 Exact Sciences Corporation Detecting esophageal disorders
US10709428B2 (en) 2015-05-01 2020-07-14 Dermtech, Inc. Non-invasive skin collection system
WO2016181393A1 (en) 2015-05-11 2016-11-17 Yeda Research And Development Co. Ltd. Citrin inhibitors for the treatment of cancer
EP3314020A1 (en) * 2015-06-29 2018-05-02 The Broad Institute Inc. Tumor and microenvironment gene expression, compositions of matter and methods of use thereof
KR101744397B1 (ko) * 2015-07-07 2017-06-08 울산대학교 산학협력단 암 진단마커로서 Uba6 또는 Use1의 용도
KR20250172724A (ko) 2015-08-31 2025-12-09 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 위 신생물 검출 방법
US11371099B2 (en) 2015-11-30 2022-06-28 Mayo Foundation For Medical Education And Research HEATR1 as a marker for chemoresistance
CA2932910A1 (en) * 2016-06-14 2017-12-14 Entos Pharmaceuticals Inc. Methods for diagnosing and treating metastatic cancer
CN106191295B (zh) * 2016-08-30 2019-07-16 梁燕华 Sharpin基因在制备诊断人皮肤肿瘤试剂中的用途
US10487365B2 (en) 2016-09-20 2019-11-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for detecting expression of lnc-FANCI-2 in cervical cells
SI3558391T1 (sl) 2016-12-23 2022-06-30 Immunogen, Inc. Imunokonjugati, ciljno usmerjeni na ADAM9, in načini njihove uporabe
AU2017382234B2 (en) 2016-12-23 2025-01-30 Macrogenics, Inc. ADAM9-binding molecules, and methods of use thereof
MY192920A (en) * 2017-03-15 2022-09-15 Cancer Res Malaysia Immunogenic peptide composition
CN107312843B (zh) * 2017-07-06 2020-08-28 北京大学深圳医院(北京大学深圳临床医学院) Krba1基因突变在制备乳腺癌检测试剂盒中的应用
JP6967810B2 (ja) * 2017-07-28 2021-11-17 レモネックス インコーポレイテッドLemonex Inc. 肝癌の予防または治療用の薬学的組成物
WO2019022586A2 (ko) * 2017-07-28 2019-01-31 주식회사 레모넥스 간암의 예방 또는 치료용 약학적 조성물
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
CN107621543B (zh) * 2017-08-30 2019-10-01 福建师范大学 Krba1蛋白在制备肝癌术后预后评估试剂盒中的应用、肝癌预后评估试剂盒及方法
KR102270926B1 (ko) * 2018-01-25 2021-06-30 주식회사 네오나 Banf1, plod3 또는 sf3b4의 억제제를 유효성분으로 포함하는 간암의 예방 및 치료용 조성물
KR102025005B1 (ko) * 2018-01-25 2019-09-24 가톨릭대학교 산학협력단 전암성 병변에서 조기 간암을 진단 및 예측할 수 있는 바이오 마커 및 이의용도
WO2019146841A1 (ko) * 2018-01-25 2019-08-01 가톨릭대학교 산학협력단 간암의 진단 및 예후 예측용 바이오 마커 및 이의 용도
US11976332B2 (en) 2018-02-14 2024-05-07 Dermtech, Inc. Gene classifiers and uses thereof in non-melanoma skin cancers
MX2020013466A (es) 2018-06-26 2021-04-19 Immunogen Inc Inmunoconjugados dirigidos a adam9 y métodos para usarlos.
CU20210002A7 (es) 2018-07-10 2021-08-06 Novartis Ag Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteína con dedos de zinc 2 de la familia ikaros (ikzf2)
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CN109722482A (zh) * 2019-01-23 2019-05-07 宁波大学 分子标志物ska2在转移性肾透明细胞癌中的应用
AU2020247911A1 (en) 2019-03-26 2021-11-11 Dermtech, Llc Novel gene classifiers and uses thereof in skin cancers
KR102203850B1 (ko) * 2019-04-09 2021-01-18 사회복지법인 삼성생명공익재단 신경교종의 진단 또는 예후 예측용 조성물 및 이에 관한 정보를 제공하는 방법
KR102042710B1 (ko) * 2019-07-02 2019-11-08 의료법인 성광의료재단 면역체크 포인트와 관련된, 난소암 진단용 바이오마커
CN111308074B (zh) * 2019-12-12 2022-11-01 中山大学附属第三医院 检测肝细胞癌诊断标志物及筛查或辅助诊断产品中的应用
AU2021410768B2 (en) 2020-12-23 2026-04-30 Regeneron Pharmaceuticals, Inc. Treatment of liver diseases with cell death inducing dffa like effector b (cideb) inhibitors
CN113238051A (zh) * 2021-02-24 2021-08-10 深圳市人民医院 一种人源mob1蛋白的应用
CN112980955A (zh) * 2021-03-05 2021-06-18 南昌大学第二附属医院 Emilin2作为胶质瘤替莫唑胺耐药检测、治疗及预后分子靶点的应用
US20240165256A1 (en) 2021-03-08 2024-05-23 Immunogen, Inc. Methods for increasing efficacy of immunoconjugates targeting adam9 for the treatment of cancer
CN113917156A (zh) * 2021-09-30 2022-01-11 复旦大学附属中山医院 Hint2在制备治疗或诊断心力衰竭药物中的用途
CN114783609B (zh) * 2022-05-11 2025-07-15 深圳市人民医院 一种基于pus家族基因的肝细胞癌预后评分系统及其应用
CN116312802B (zh) * 2023-02-01 2023-11-28 中国医学科学院肿瘤医院 一种特征基因trim22用于制备调控乳腺癌相关基因表达的试剂的应用
CN116617245B (zh) * 2023-02-17 2023-11-10 新乡医学院 Utp11抑制剂及其在肿瘤抑制中的用途
CN116356023A (zh) * 2023-03-01 2023-06-30 河北工业大学 Clcn7在制备癌症诊疗产品中的应用
CN116482364B (zh) * 2023-03-10 2025-09-26 重庆医科大学附属第二医院 sNINJ1作为血清标志物在肝癌诊断、预后与疗效评估、治疗中的应用
CN116769916B (zh) * 2023-06-27 2025-03-07 南通大学附属医院 Tmed8基因在制备胰腺癌药物及其诊断试剂盒中的应用
CN117089621B (zh) * 2023-09-28 2024-06-25 上海爱谱蒂康生物科技有限公司 生物标志物组合及其在预测结直肠癌疗效中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281091A1 (en) * 2003-07-07 2006-12-14 Lavedan Christian N Genes regulated in ovarian cancer a s prognostic and therapeutic targets
WO2007038792A2 (en) * 2005-09-28 2007-04-05 H. Lee Moffitt Cancer Center Individualized cancer treatments
WO2010065940A1 (en) * 2008-12-04 2010-06-10 The Regents Of The University Of California Materials and methods for determining diagnosis and prognosis of prostate cancer

Also Published As

Publication number Publication date
US20140342946A1 (en) 2014-11-20
WO2013098797A3 (en) 2013-09-12
WO2013098797A2 (en) 2013-07-04

Similar Documents

Publication Publication Date Title
WO2013098797A3 (en) Diagnostic tests for predicting prognosis, recurrence, resistance or sensitivity to therapy and metastatic status in cancer
Gao et al. LncRNA PCAT1 activates SOX2 and suppresses radioimmune responses via regulating cGAS/STING signalling in non‐small cell lung cancer
Kong et al. Transposable element expression in tumors is associated with immune infiltration and increased antigenicity
Yang et al. CD73, tumor plasticity and immune evasion in solid cancers
Hess et al. MiR-200b and miR-155 as predictive biomarkers for the efficacy of chemoradiation in locally advanced head and neck squamous cell carcinoma
Hahne et al. Non-coding RNAs and resistance to anticancer drugs in gastrointestinal tumors
Mathe et al. MiRNAs and other epigenetic changes as biomarkers in triple negative breast cancer
Chen et al. Identification of microRNA‐214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression
Marino et al. Prognostic significance of miR-34a in Ewing sarcoma is associated with cyclin D1 and ki-67 expression
Kotsifaki et al. Unveiling the immune microenvironment’s role in breast cancer: a glimpse into promising frontiers
WO2012153187A3 (en) Markers for cancer prognosis and therapy and methods of use
WO2012103250A3 (en) Colon cancer gene expression signatures and methods of use
EP4410978A3 (en) Methods for quantitative genetic analysis of cell free dna
WO2009149026A3 (en) Genomic approaches to fetal treatment and diagnosis
WO2011153545A3 (en) Gene expression signature as a predictor of chemotherapeutic response in breast cancer
WO2011122857A3 (ko) 유방암 예후 예측을 위한 조성물 및 이를 포함하는 키트
Lu et al. Transcriptome sequencing investigated the tumor-related factors changes after T. gondii infection
MX2013008252A (es) Firma de pronostico para la recurrencia de cancer colorrectal.
Bertoni et al. Integrative meta-analysis identifies microRNA-regulated networks in infantile hemangioma
Shen et al. Ferroptosis biomarkers for predicting prognosis and immunotherapy efficacy in adrenocortical carcinoma
WO2008137090A3 (en) Knowledge-based proliferation signatures and methods of use
El-Tanani et al. Deciphering the role of cancer stem cells: drivers of tumor evolution, therapeutic resistance, and precision medicine strategies. Cancers (Basel). 2025; 17 (3): 382
WO2008137089A3 (en) Gene signature of early hypoxia to predict patient survival
WO2016060537A3 (fr) Sondes et amorces pour la quantification rapide et fiable des gènes spécifiques au cancer de la prostate en utilisant des gènes contrôles adéquats
Qusairy et al. Bruton’s Tyrosine Kinase: A Double-Edged Sword in Cancer and Aging